| Autor: |
Kramer J; Charles River Laboratories, Cleveland, OH, USA., Himmel HM; Safety Pharmacology, Bayer AG, Wuppertal, Germany., Lindqvist A; Sophion Bioscience A/S, Ballerup, Denmark., Stoelzle-Feix S; Nanion Technologies GmbH, Munich, Germany., Chaudhary KW; Global Safety Pharmacology, GlaxoSmithKline PLC, Collegeville, PA, USA., Li D; Drug Safety Research & Development, Pfizer, Groton, CT, USA., Bohme GA; Integrated Drug Discovery, High Content Biology Unit, Sanofi R&D, Vitry-Sur-Seine, France., Bridgland-Taylor M; Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, Astra Zeneca, Cambridge, UK., Hebeisen S; B'SYS GmbH, Witterswil, Switzerland., Fan J; Discovery Toxicology, Bristol-Myers Squibb Company, Princeton, NJ, USA., Renganathan M; Eurofins Discovery, St. Charles, MO, USA., Imredy J; Merck & Co., Inc., Kenilworth, NJ, USA., Humphries ESA; Metrion Biosciences Ltd., Cambridge, UK., Brinkwirth N; Nanion Technologies GmbH, Munich, Germany., Strassmaier T; Nanion Technologies, Livingston, NJ, USA., Ohtsuki A; Nanion Technologies Japan K.K., Shinjyuku-ku, Tokyo, Japan., Danker T; Natural and Medical Science Institute at the University of Tübingen, Reutlingen, Germany., Vanoye C; Northwestern Feinberg School of Medicine, Chicago, IL, USA., Polonchuk L; Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland., Fermini B; Novoheart, Vancouver, BC, Canada., Pierson JB; Health and Environmental Sciences Institute, Washington, DC, USA. Jpierson@hesiglobal.org., Gintant G; AbbVie, Chicago, IL, USA. |
